PRPO:NASDAQPrecipio, Inc. Analysis
Data as of 2026-04-25 - not real-time
$28.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Precipio, Inc. (PRPO) is trading near the upper end of its 20‑day SMA ($27.18) and above both its 50‑day ($26.36) and 200‑day ($21.47) averages, suggesting a short‑term bullish bias. However, the MACD histogram has turned negative (-0.095) and the RSI sits at a neutral 53, while volume is trending down, indicating weakening momentum as the stock approaches its technical resistance around $29.80. The company posted strong top‑line growth (22.9% YoY revenue increase to $24M) and achieved positive operating cash flow in 2025, highlighted in recent earnings call transcripts, and even saw insider buying (COO purchased shares at $27.93). Despite these operational improvements, valuation metrics remain stretched: the forward PE of 71.8 far exceeds the industry average of 25.4, and a DCF‑derived fair value of $3.45 is dramatically below the current price of $27.99, flagging a severe overvaluation risk.
Given the high 30‑day volatility (≈65%), low beta (~0.33), and a lack of dividend, the stock presents a mixed picture—promising fundamentals counterbalanced by technical softness and an inflated market price. Investors should weigh the upside from continued cash‑flow generation against the downside risk of a valuation correction.
Given the high 30‑day volatility (≈65%), low beta (~0.33), and a lack of dividend, the stock presents a mixed picture—promising fundamentals counterbalanced by technical softness and an inflated market price. Investors should weigh the upside from continued cash‑flow generation against the downside risk of a valuation correction.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Technical momentum turning bearish (negative MACD histogram, decreasing volume)
- Price near resistance with limited upside
- Severe valuation gap (price far above DCF fair value)
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained revenue growth and positive cash flow generation
- Insider confidence reflected by recent COO share purchase
- Valuation still elevated but potential for price stabilization
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Long‑term growth prospects in cancer diagnostics market
- Improving operating margins and cash conversion
- Risk that valuation correction may offset upside from fundamentals
Key Metrics & Analysis
Financial Health
Revenue Growth22.90%
Profit Margin-1.51%
P/E Ratio71.8
ROE-2.72%
ROA-3.92%
Debt/Equity25.09
P/B Ratio3.4
Op. Cash Flow$685.0K
Free Cash Flow$210.1K
Industry P/E25.4
Technical Analysis
TrendBullish
RSI53.3
Support$23.70
Resistance$29.80
MA 20$27.18
MA 50$26.36
MA 200$21.47
MACDBearish
VolumeDecreasing
Fear & Greed Index88.02
Valuation
Fair Value$3.45
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.33
Volatility65.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.